Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(H Share Stock Code: 0874)

ANNOUNCEMENT OF RESOLUTIONS PASSED AT THE 3rd MEETING OF THE FIFTH SESSION OF THE BOARD

Guangzhou Pharmaceutical Company Limited (the "Company") and all members of the Board of directors (the "Board") hereby confirm the truthfulness, accuracy and completeness of the contents of this announcement and jointly and severally accept full responsibility for any false representation, misleading statement or material omission herein contained.

The 3rd meeting of the fifth session of the Board of the Company was held by way of written resolution on 29 September 2010. The meeting was in compliance with the requirements of the Company Law and the Articles of Association of the Company.

After due consideration by the Board, the resolution on change of joint company secretary was passed with 9 affirmative votes, 0 dissenting vote and 0 vote abstaining from voting (details of the change of joint company secretary are set out in the Company's announcement dated 29 September 2010).

This announcement is made pursuant to Rule 13.09 (2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Board of **Guangzhou Pharmaceutical Company Limited**

Guangzhou, the PRC, 29 September 2010

As at the date of this announcement, the Board comprises Mr. Yang Rongming, Mr. Li Chuyuan, Mr. Shi Shaobin and Mr. Wu Changhai as executive directors, and Mr. Liu Jinxiang, Mr. Li Shanmin, Mr. Zhang Yonghua, Mr. Wong Lung Tak Patrick and Mr. Qiu Hongzhong as independent non-executive directors.